The state of North Carolina currently has 18 active clinical trials seeking participants for Ulcerative Colitis research studies. These trials are conducted in various cities, including Durham, Winston-Salem, Charlotte and Chapel Hill.
A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA)
NCT06127043
Recruiting
ROSETTA STUDY: This study will evaluate the safety, tolerability, and efficacy of Rosnilimab in subjects with moderate to severe ulcerative colitis (UC)
Gender:
All
Ages:
18 years and above
Trial Updated:
04/16/2024
Locations: AnaptysBio Investigative Site 10-105, Winston-Salem, North Carolina
Conditions: Ulcerative Colitis
Register for Updates
A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease
NCT03251118
Recruiting
TARGET-IBD is a 5-year, longitudinal, observational study of adult and pediatric patients (age 2 and above) being managed for Inflammatory Bowel Disease (IBD) in usual clinical practice. TARGET-IBD will create a research registry of patients with IBD within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
Gender:
All
Ages:
2 years and above
Trial Updated:
10/27/2023
Locations: Cary Gastroenterology Associates, Cary, North Carolina +3 locations
Conditions: Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis
Register for Updates
Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis
NCT04314375
Recruiting
This is a randomized, double-blind, placebo-controlled, multicenter, study to evaluate the efficacy, safety, and pharmacokinetics (PK) of budesonide extended-release tablets for the induction of remission in pediatric subjects, with active, mild to moderate ulcerative colitis (UC). Subjects will be permitted to continue taking background oral or rectal 5-aminosalicylate (5-ASA) products.
Gender:
All
Ages:
Between 5 years and 17 years
Trial Updated:
10/05/2023
Locations: Bausch Health Site 010, Greenville, North Carolina
Conditions: Ulcerative Colitis
Register for Updates
A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis
NCT05181137
Recruiting
This is a randomized, double-blind, placebo-controlled, multicenter Phase 3 study that will enroll approximately 368 subjects aged 18 to 75 years old with Moderately to Severely Active Ulcerative Colitis.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
09/01/2023
Locations: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina +1 locations
Conditions: Ulcerative Colitis
Register for Updates
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy
NCT05316584
Recruiting
The investigators hypothesize that use of a remote monitoring digital health system that supports medication taking and monitoring of symptoms will improve adherence, clinical outcomes, and decrease healthcare utilization compared to standard care in participants with inflammatory bowel disease initiating oral or subcutaneous treatment. The investigators are conducting a 12-month, multicenter, randomized, controlled trial to assess the feasibility and effectiveness of a remote monitoring digital... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
04/26/2023
Locations: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Conditions: Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Register for Updates
An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT04718818
Recruiting
The present study D5272C00001 (Legacy # 3151-201-008) seeks to evaluate the efficacy and safety of brazikumab versus placebo in patients with moderately to severely active UC and will include assessments of clinical responses as demonstrated by improvement of symptoms and of colonic mucosal appearance as observed on endoscopy.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
01/19/2021
Locations: Research Site, Morehead City, North Carolina
Conditions: Ulcerative Colitis
Register for Updates